| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
59,660,000 |
| Market
Cap: |
193.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.3 - $9.33 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Leap Therapeutics is a biopharmaceutical company developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Co.'s primary clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. Co. is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gilead Sciences Inc |
10% Owner |
– – • |
2024-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,319,148 |
|
4% |
|
| Onsi Douglas E |
CEO,CFO,Pres.,GC,Treas.,&Sec. |
• • – |
2024-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
73,646 |
|
- |
|
| Lawlor Augustine |
Chief Operating Officer |
• – – |
2024-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,086 |
|
- |
|
| Omahony John Mark |
Chief Manufacturing Officer |
• – – |
2024-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Sirard Cynthia |
Chief Medical Officer |
• – – |
2024-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Miraelli Christopher |
Chairman of the Board |
• • – |
2024-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,086 |
|
- |
|
| Onsi Douglas E |
CEO,CFO,Pres.,GC,Treas.,&Sec. |
• • – |
2023-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
660,606 |
661,466 |
|
- |
|
| Beigene, Ltd. |
10% Owner |
– – • |
2021-09-24 |
4 |
B |
$2.85 |
$7,249,830 |
D/D |
2,543,800 |
7,348,437 |
2.45 |
-44% |
|
| Healthcare Partners Viii, L.p. |
10% Owner |
– – • |
2020-12-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,618,406) |
0 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2020-06-22 |
4 |
B |
$2.00 |
$3,500,000 |
I/I |
1,750,000 |
8,476,496 |
1.5 |
-8% |
|
| Beigene, Ltd. |
10% Owner |
– – • |
2020-03-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,804,637 |
|
26% |
|
| Onsi Douglas E |
CFO, GC, Treasurer & Secretary |
• – • |
2019-02-05 |
4 |
B |
$1.75 |
$999,999 |
I/I |
571,428 |
4,114,804 |
3.36 |
- |
|
| Healthcare Partners Ix, Llc |
10% Owner |
– – • |
2019-02-05 |
4 |
B |
$1.75 |
$999,999 |
D/D |
571,428 |
4,144,804 |
2.45 |
- |
|
| Miraelli Christopher |
CEO, President, Chairman |
• • • |
2019-02-05 |
4 |
B |
$1.75 |
$999,999 |
I/I |
571,428 |
4,114,804 |
2.64 |
- |
|
| Lawlor Augustine |
Chief Operating Officer |
• – • |
2019-02-05 |
4 |
B |
$1.75 |
$999,999 |
I/I |
571,428 |
4,114,804 |
3.36 |
- |
|
| Onsi Douglas E |
CFO, GC, Treasurer & Secretary |
• – • |
2017-11-14 |
4 |
B |
$6.09 |
$6,436,524 |
I/I |
1,057,769 |
3,573,376 |
3.36 |
- |
|
| Miraelli Christopher |
CEO, President, COB |
• • • |
2017-11-14 |
4 |
B |
$6.09 |
$6,436,524 |
I/I |
1,057,769 |
3,573,376 |
2.64 |
- |
|
| Healthcare Partners Ix, Llc |
10% Owner |
– – • |
2017-11-14 |
4 |
B |
$6.09 |
$6,436,524 |
D/D |
1,057,769 |
3,573,376 |
2.45 |
- |
|
| Lawlor Augustine |
Chief Operating Officer |
• – • |
2017-11-14 |
4 |
B |
$6.09 |
$6,436,524 |
I/I |
1,057,769 |
3,573,376 |
3.36 |
- |
|
| Werner Harold R |
10% Owner |
– – • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,618,406 |
|
- |
|
| Miraelli Christopher |
CEO,Pres,Chairman of the Board |
• • • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,477,902 |
|
- |
|
| Littlechild John W |
Director |
– • • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,618,406 |
|
- |
|
| Cavanaugh James H |
Director |
– • • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,618,406 |
|
- |
|
| Lawlor Augustine |
Chief Operating OfficerOfficer |
• – • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,477,902 |
|
- |
|
| Onsi Douglas E |
CFO,Gen Counsel,Treas, Sec.Off |
• – • |
2017-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,859,496 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (2.52%) 
